Table 2.
Treatment outcomes of patients with non-infectious uveitis treated with methotrexate.
| Base line | 3 months | 6 months | 12 months | 18 months | 24 months | |
|---|---|---|---|---|---|---|
| Number of patients (eyes) | 35 (65) | 35 (65) | 35 (65) | 26 (47) | 17 (30) | 14 (23) |
| Mean dose of methotrexate (mg/week) | 0 | 9.2 | 10.5 | 10.6 | 9.2 | 9 |
| Systemic corticosteroids | ||||||
| Mean dose of systemic corticoteroids (mg/day) | 12.1 | 3.1* | 1.3* | 0.6* | 0* | 0* |
| Percentage of patients with corticosteroids ≤ 5 mg | 34.3 | 72.3 | 94.3 | 96.3 | 100 | 100 |
| Percentage of corticosteroid-free patients | 22.9 | 45.7 | 68.6 | 88.9 | 100 | 100 |
| Steroid eye drops | ||||||
| Percentage of patients with bethamethasone ≥ 2 times daily | 80 | 58.4 | 58.4 | 40.3 | 30 | 43.4 |
| Percentage of patients with fluorometholone ≤ 2 times daily | 8 | 21.5 | 24.6 | 34 | 40 | 39.1 |
| None | 1.5 | 9.2 | 13.3 | 14.9 | 26.7 | 26.1 |
| Percentage of patients with intraocular pressure-lowering eye drops | 36.9 | 46.2 | 46.2 | 38.3 | 36.7 | 34.8 |
| Mean best corrected visual acuity (logarithm of the minimal angle of resolution) | 0.12 | 0.09 | 0.07 | 0.05 | −0.04 | −0.06 |
| Percentage of eyes with of ≤ 0.5 + anterior chamber cells | 32.3 | 61.5 | 73.8 | 74.5 | 83.3 | 76.2 |
| Percentage of eyes with ≤ 0.5 + vitreous haze | 72.3 | 86.2 | 87.7 | 89.4 | 100 | 100 |
| Percentage of eyes with cystic macular edema | 90.8 | 95.4 | 96.2 | 95.7 | 100 | 100 |
| Percentage of eyes without active retinal/choroidal lesion | 44.6 | 60 | 70.8 | 83 | 96.7 | 100 |
| Percentage of eyes with inactive uveitis | 0 | 29.2 | 49.2 | 59.6 | 80 | 90 |
*
Significant difference observed between baseline and evaluation point (Steel test, p < 0.05).